Envarsus is named as an intervention in 4 current clinical trials in our Germany and Canada registers. 2 are recruiting patients now. All registered phases are Phase 4. The sponsor with the most trials is Edward Geissler (2). The most-studied condition is Immunosuppression.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
NCT05089604 · ClinicalTrials.gov ↗ · Liver Transplantation, Immunosuppression, Neurotoxicity
|
Phase 4 | Recruiting | University of British Columbia | Canada |
|
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
NCT06268769 · ClinicalTrials.gov ↗ · Immunosuppression
|
Phase 4 | Recruiting | Edward Geissler | Germany |
|
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
NCT05655273 · ClinicalTrials.gov ↗ · Liver Transplant Rejection, Immune System Suppression
|
Phase 4 | By invitation | University Health Network, Toronto | Canada |
|
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients
NCT04720326 · ClinicalTrials.gov ↗ · Prophylaxis Against Liver Transplant Rejection
|
Phase 4 | Active, closed | Edward Geissler | Germany |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Edward Geissler | 2 |
| University of British Columbia | 1 |
| University Health Network, Toronto | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Germany | 2 | 1 |
| Clinical trials in Canada | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our Germany and Canada registers name Envarsus as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 1 with sites in Germany and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Edward Geissler (2), University of British Columbia (1) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Envarsus works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Envarsus works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Envarsus (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.